1. Currently pregnant or last pregnancy outcome within 3 months prior to enrolment 
2. Currently breast-feeding 
3. Participated in any other research study within 60 days prior to screening 
4. Previously participated in any HIV vaccine study 
5. Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks prior to enrollment 
6. Presence of abnormal physical finding on the vulva, vaginal walls or cervix during pelvic/speculum examination and/or colposcopy 
7. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction 
8. Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation 
9. Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory abnormality according to the DAIDS Table for Grading Adverse Experiences 
10. Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment 
11. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex 
12. Any serious acute, chronic or progressive disease 
13. Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives       
    

NCT00917891_exc_T1
Condition
pregnant
NCT00917891_exc_T2
Condition
pregnancy outcome
NCT00917891_exc_T3
Temporal
within 3 months prior to enrolment
NCT00917891_exc_T4
Reference_point
enrolment
NCT00917891_exc_T6
Qualifier
last
NCT00917891_exc_T7
Temporal
last
NCT00917891_exc_T8
Condition
breast-feeding
NCT00917891_exc_T9
Temporal
Currently
NCT00917891_exc_T10
Temporal
Currently
NCT00917891_exc_T12
Condition
urogenital infections
NCT00917891_exc_T13
Qualifier
Untreated
NCT00917891_exc_T14
Condition
symptomatic
NCT00917891_exc_T15
Condition
asymptomatic
NCT00917891_exc_T16
Scope
symptomatic or asymptomatic
NCT00917891_exc_T17
Temporal
within 2 weeks prior to enrollment
NCT00917891_exc_T18
Reference_point
enrollment
NCT00917891_exc_T19
Condition
abnormal physical finding on the vulva
NCT00917891_exc_T20
Condition
abnormal physical finding on the vaginal walls
NCT00917891_exc_T21
Condition
abnormal physical finding on the cervix
NCT00917891_exc_T22
Procedure
speculum examination
NCT00917891_exc_T23
Procedure
pelvic examination
NCT00917891_exc_T24
Procedure
colposcopy
NCT00917891_exc_T25
Scope
pelvic/speculum examination and/or colposcopy
NCT00917891_exc_T26
Scope
abnormal physical finding on the vulva, vaginal walls or cervix
NCT00917891_exc_T27
Condition
urogenital prolapse
NCT00917891_exc_T28
Condition
uterine prolapse
NCT00917891_exc_T29
Condition
vaginal bleeding
NCT00917891_exc_T30
Qualifier
undiagnosed
NCT00917891_exc_T31
Condition
urethral obstruction
NCT00917891_exc_T32
Qualifier
significant
NCT00917891_exc_T33
Observation
History
NCT00917891_exc_T34
Scope
urogenital or uterine prolapse
NCT00917891_exc_T36
Measurement
Pap smear
NCT00917891_exc_T37
Temporal
at screening
NCT00917891_exc_T38
Value
requires cryotherapy
NCT00917891_exc_T39
Value
requires biopsy
NCT00917891_exc_T40
Value
requires treatment
NCT00917891_exc_T41
Procedure
cryotherapy
NCT00917891_exc_T42
Procedure
biopsy
NCT00917891_exc_T43
Procedure
treatment
NCT00917891_exc_T44
Value
requires further evaluation
NCT00917891_exc_T45
Procedure
further evaluation
NCT00917891_exc_T46
Scope
requires cryotherapy, biopsy, treatment or further evaluation
NCT00917891_exc_T47
Condition
laboratory abnormality
NCT00917891_exc_T48
Condition
urinalysis abnormality
NCT00917891_exc_T49
Condition
chemistry abnormality
NCT00917891_exc_T50
Condition
haematology abnormality
NCT00917891_exc_T51
Value
Grade 2, 3 or 4
NCT00917891_exc_T52
Temporal
baseline
NCT00917891_exc_T53
Measurement
DAIDS Table for Grading Adverse Experiences
NCT00917891_exc_T54
Procedure
haematology
NCT00917891_exc_T55
Procedure
chemistry
NCT00917891_exc_T56
Procedure
urinalysis
NCT00917891_exc_T57
Procedure
laboratory
NCT00917891_exc_T58
Condition
bleeding per vagina
NCT00917891_exc_T59
Qualifier
undiagnosed
NCT00917891_exc_T60
Qualifier
Unexplained
NCT00917891_exc_T61
Qualifier
abnormal
NCT00917891_exc_T62
Condition
bleeding per vagina
NCT00917891_exc_T63
Temporal
during vaginal intercourse
NCT00917891_exc_T64
Temporal
following vaginal intercourse
NCT00917891_exc_T65
Procedure
gynaecologic surgery
NCT00917891_exc_T66
Temporal
within 90 days prior to enrollment
NCT00917891_exc_T67
Reference_point
enrollment
NCT00917891_exc_T68
Scope
during or following vaginal intercourse
NCT00917891_exc_T69
Scope
bleeding per vagina, bleeding per vagina
NCT00917891_exc_T70
Scope
Unexplained, undiagnosed abnormal
NCT00917891_exc_T71
Condition
anaphylaxis
NCT00917891_exc_T72
Observation
history
NCT00917891_exc_T73
Condition
allergy
NCT00917891_exc_T74
Qualifier
severe
NCT00917891_exc_T75
Condition
angioedema
NCT00917891_exc_T76
Observation
history
NCT00917891_exc_T77
Condition
sensitivity to latex
NCT00917891_exc_T78
Condition
allergy to latex
NCT00917891_exc_T79
Scope
sensitivity/allergy to latex
NCT00917891_exc_T80
Scope
anaphylaxis or severe allergy
NCT00917891_exc_T81
Condition
disease
NCT00917891_exc_T82
Qualifier
progressive
NCT00917891_exc_T83
Multiplier
chronic
NCT00917891_exc_T84
Temporal
acute
NCT00917891_exc_T85
Qualifier
serious
NCT00917891_exc_T86
Scope
serious acute, chronic or progressive